News
Resources
Blog
Sites
Stephen J. Ubl Stephen J. Ubl is president and chief executive officer of PhRMA. Mr. Ubl leads PhRMA’s work preserving and strengthening a health care and economic environment that encourages medical innovation, new drug discovery and access to life-saving medicines. Ubl is recognized around the world as a leading health care advocate and policy expert who collaborates successfully with diverse stakeholder groups – including patient and physician groups, regulators, public and private payers, and global trade organizations – to help ensure timely patient access to innovative treatments and cures.
Recent Posts
Copay assistance is a lifeline for patients. So why are insurers blocking it?
By Stephen J. Ubl | June 29, 2022
In today’s broken insurance system, patients too often pay more for a medicine than what their insurance company pays.
Read More
Biopharmaceutical researchers to discuss the value of R&D with Congress
By Stephen J. Ubl | June 9, 2022
Today, researchers from PhRMA member companies will meet virtually with members of Congress and Capitol Hill staff to discuss the importance of biopharmaceutical innovation in bringing new treatments...
Read More
A conversation with Barry Greene, CEO of Sage Therapeutics
By Stephen J. Ubl | May 4, 2022
Our industry continues working to build a more resilient, affordable and equitable health care system. As part of Mental Health Awareness Month, I recently had the opportunity to connect with PhRMA...
Read More
Upcoming graduate student summit will showcase pathways to success within the biopharmaceutical industry
By Stephen J. Ubl | September 28, 2021
I am excited to join with Dr. Michael L. Lomax, President & CEO, UNCF; Dr. James Gillespie, President & Co-Founder, Center for Healthcare Innovation (CHI); and Dr. Chad Womack, Co-Founder and...
Read More
A global focus on ending the COVID-19 pandemic
By Stephen J. Ubl | September 22, 2021
Today, President Biden convened global leaders to confront the challenges around ending this pandemic. We stand with the president, all governments, organizations and sectors in a shared commitment...
Read More
America’s biopharmaceutical companies to Congress: Government “negotiation” is the wrong approach
By Stephen J. Ubl | September 15, 2021
Today, PhRMA member companies made public an open letter to Capitol Hill to encourage Congress to abandon old partisan ideas on drug pricing and instead pursue policies that actually address what...
Read More
The future of the rebate rule: Will policymakers stand with patients?
By Stephen J. Ubl | August 2, 2021
Policymakers will soon decide whether to stand by new Medicare changes that will help lower costs for beneficiaries at the pharmacy counter or abandon these changes to fund government programs...
Read More
Building a better health care system: A conversation with Mark Reisenauer, President of Astellas US
By Stephen J. Ubl | June 23, 2021
Our industry continues to work tirelessly to combat the COVID-19 virus by developing effective therapeutics to treat COVID-19 and vaccines to prevent future infections. As we continue our efforts to...
Read More
PhRMA hosts first stakeholder workshop on clinical trial diversity
By Stephen J. Ubl | June 11, 2021
This week, 500+ health care and community members from over 150 organizations came together at PhRMA’s first stakeholder workshop focused on improving diversity in clinical trials. At the virtual...
Read More
How research evolves and brings new hope to patients
By Stephen J. Ubl | June 11, 2021
Before medicines can be made available to patients, they often begin as ideas that are based on newly discovered molecules and cells, strange phenomena or little-understood processes in the body. The...
Read More
Medicare Monday (100)
340B Spotlight (46)
Cost & Consequence (0)
